Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00805181
NCT00805181CompletedNot Applicable

Kinetics of Procalcitonin, C-reactive Protein and Pyuria in Uncomplicated Pyelonephritis in Women: A Pilot Study

University Hospital, Geneva1 site in 1 country30 target enrollmentStarted: December 2008Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
30
Locations
1
Primary Endpoint
Blood and urine biomarkers (procalcitonin, C-reactive protein, SIGNATURE(TM) test, pyuria
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The objective of this study is to explore the kinetics of biomarkers in 30 adult female patients with uncomplicated acute pyelonephritis.

Detailed Description

We will measure c-reactive protein, procalcitonin, pyuria and a new blood biomarker (Signature TM) everyday till normalization of these markers in 30 adult female patients with uncomplicated acute pyelonephritis.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •> 18 years
  • •Flank/loin pain or tenderness, or both and fever > 38°C during the last 48 hours and pyuria

Exclusion Criteria

  • •Pregnancy
  • •Presence of indwelling catheters
  • •Known polycystic kidney disease or any malformation of the urinary tract, or single kidney; renal transplant recipients; acute or chronic renal failure requiring dialysis
  • •Recent discharge from hospital (during the last 10 days); ongoing antibiotic treatment
  • •Known severe immunosuppression: Receiver of solid-organ or hematopoietic stem cells transplants; neutropenia ( < 1 G neutrophils / L); chronic (more than 14 days) use of systemic glucocorticoids (>10 mg/d of prednisone); active use of immunosuppressive therapy for the treatment of auto-immune or inflammatory disease; HIV infection with < 350 CD4+ cells / ml or unknown CD4+ status
  • •Pyelonephritis initially identified as complicated: obstruction of urinary tract, urinary stone; history of renal infection in the last 15 days
  • •Patient with severe sepsis or septic shock

Outcomes

Primary Outcomes

Blood and urine biomarkers (procalcitonin, C-reactive protein, SIGNATURE(TM) test, pyuria

Time Frame: Daily till day 15.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other

Study Sites (1)

Loading locations...

Similar Trials

Withdrawn
Not Applicable
Procalcitonin Versus C-reactive Protein to Guide Therapy in Community Acquired PneumoniaCommunity-acquired Pneumonia
NCT01018199Federal University of Minas Gerais
Completed
Not Applicable
Predictive Value of Procalcitonin, CRP, Drain Fluid Culture, Il-6 and Tnf-α in Anastomotic LeakageAnastomotic Leakage in Colon Surgery
NCT02361918Istanbul University50
Completed
Not Applicable
BIOmarkers of Dyspnea IN Emergency RoomSevere DyspneaCAPDAE COPDAcute Heart FailurePulmonary Embolism
NCT01227317ThermoFisher Scientific Brahms Biomarkers France444
Completed
Not Applicable
Procalcitonin Use in Pneumonia Patients in the Critical Care SettingPneumonia
NCT01788488Mayo Clinic134
Recruiting
Not Applicable
Evaluating the role of serum procalcitonin and c-reactive protein as a marker for serious infection in young childre
CTRI/2012/05/002633MAX SUPER SPECIALITY HOSPITA40